Factors Associated with Treatment Outcome of Shorter Treatment Regimen (STR) for MultiDrug-Resistant Tuberculosis (MDR-TB)
DOI:
https://doi.org/10.32734/jetromi.v6i4.16123Keywords:
Treatment Outcome, Shorter Treatment Regimen, MDR-TBAbstract
ABSTRACT
Background: Indonesia ranked 2nd around the world for TB cases with case population continue increasing. In 2018, Shorter Treatment Regimen (STR) was introduced as a new regimen for treating MDR-TB patient. The aim of this study is to determine factors associated with treatment outcome of MDR-TB patients treated with Shorter Treatment Regimen
Methods: This is a descriptive-analytic study using cross sectional design which was conducted at Adam Malik Hospital Medan. Subject was 150 patients with drug-resistant Pulmonary TB at MDR-TB polyclinics according to inclusion and exclusion criteria
Results: MDR-TB patients that treated with STR was mostly < 50 years old (65.2%) and 107 subjects (70.4%) were male. The majority of subjects with comorbidity were 94 subjects (61.8%); 43 subjects (28.3%) with DM, 5 subjects (3.3%) with CHF, 3 subjects (2.0%) with HIV, 1 subject (0.7%) with DM & CHF, and 1 subject (0.7%) with DM & HIV. When evaluated the patients treatment outcome, 47.4% were cured, 6.6% were failed, 34.8% were default and 11.2% were death. A chi square test was conducted to assess association between age with treatment outcome. Age was significantly associated with treatment outcome (p=0.038) but gender and comorbidity were not associated with treatment outcome with p-value 0.152 and 0.497 (p>0,05) respectively.
Conclusions: There is a significant association between age and treatment outcome but no significant association between gender and comorbidity with treatment outcome.
ABSTRAK
Latar Belakang: Indonesia menduduki peringkat ke-2 dunia untuk kasus TBC dengan populasi kasus yang terus meningkat. Pada tahun 2018, Shorter Treatment Regimen (STR) diperkenalkan sebagai rejimen baru untuk mengobati pasien TB-MDR. Tujuan dari penelitian ini adalah untuk mengetahui faktor-faktor yang berkorelasi dengan hasil pengobatan pasien TB-MDR yang diobati dengan Regimen STR.
Metode: Penelitian ini merupakan penelitian deskriptif-analitik dengan desain cross-sectional yang dilakukan di Rumah Sakit Adam Malik Medan. Subyek penelitian adalah 150 pasien TB Paru Resisten Obat di poliklinik TB MDR sesuai kriteria inklusi dan eksklusi.
Hasil: Pasien TB-MDR yang diobati dengan STR sebagian besar berusia <50 tahun (65,2%) dan berjenis kelamin laki-laki sebanyak 107 subjek (70,4%). Mayoritas subjek dengan penyakit penyerta sebanyak 94 orang (61,8%); 43 orang (28,3%) DM, 5 orang (3,3%) CHF, 3 orang (2,0%) HIV, 1 orang (0,7%) DM & CHF, dan 1 orang (0,7%) DM & HIV. Hasil pengobatan adalah 47,4% sembuh, 6,6% gagal, 34,8% putus berobat dan 11,2% meninggal. Uji chi square dilakukan untuk menilai hubungan antara usia dengan hasil pengobatan dan didapatkan nilai p = 0,038 yang menunjukkan adanya hubungan yang signifikan namun berdasarkan jenis kelamin dan penyakit penyerta ditemukan nilai p masing-masing 0,152 dan 0,497 (p>0,05) yang menunjukkan tidak ada hubungan antara jenis kelamin dan penyakit penyerta terhadap hasil pengobatan.
Kesimpulan: Terdapat hubungan yang signifikan antara usia dan hasil pengobatan namun tidak ada hubungan yang signifikan antara jenis kelamin dan penyakit penyerta dengan hasil pengobatan.
Downloads
Published
Issue
Section
Copyright (c) 2024 Journal of Endocrinology, Tropical Medicine, and Infectious Disease (JETROMI)
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The Authors submitting a manuscript do so on the understanding that if accepted for publication, copyright of the article shall be assigned to Journal of Endocrinology, Tropical Medicine and Infectious Diseases (JETROMI).
Copyright encompasses exclusive rights to reproduce and deliver the article in all form and media. The reproduction of any part of this journal, its storage in databases and its transmission by any form or media, will be allowed only with a written permission from Journal of Endocrinology, Tropical Medicine and Infectious Diseases (JETROMI).